The developing link between AFP-L3+/DCP+ and biologically aggressive, viable HCC are aligned with pre-surgical multi-biomarker liver transplant studies linking expression with the presence of viable tumor with aggressive biological features and the risk of post-transplant disease recurrence [16, 25–27]. This evidence concerns the gene ACE and hepatocellular carcinoma.